Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF

Rein Therapeutics, Inc.

2024-Q2 EPS reported -$1.13

Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
Cash $21.9M as of June 30, 2024; raised $18.2M net from May 2024 registered direct offering.
Cohort 1 of Phase 1b LTI-03 (2.5 mg BID) showed positive trends in 7 of 8 biomarkers with statistical significance in 3 fibrosis-related biomarkers.
LTI-03 was generally well-tolerated; topline results from high-dose Cohort 2 expected in Q3 2024.
Company expects cash to fund operations into second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.